Azithromycin reduces exacerbations in uncontrolled asthma — that much is established from clinical trials — but why has been unclear, with antibacterial, anti-inflammatory and antiviral mechanisms all proposed. AZIMUNE was designed to look directly. Forty adults with uncontrolled asthma were randomised in this investigator-initiated, double-blind, placebo-controlled trial to azithromycin 500 mg three times weekly or matching placebo for 12 weeks. Bronchial epithelial cells were obtained by bronchoscopy at baseline and at week 12, then cultured and infected with rhinovirus ex vivo.
Azithromycin increased rhinovirus-induced interferon beta (p=0.047) and interferon lambda (p=0.013) compared with baseline, with no change in the placebo group. It also reduced interleukin-33 (p=0.001), an epithelial alarmin that drives type 2 inflammation, while thymic stromal lymphopoietin was unaffected. Clinical outcomes improved numerically on azithromycin but the differences against placebo were not statistically significant.
This is a mechanism study in 32 analysed patients, and it should be read as one. It does not show azithromycin improves asthma control — the trial was far too small for that and did not find it. What it does is give a coherent explanation for an effect already demonstrated elsewhere: impaired epithelial interferon responses are thought to make asthmatic airways vulnerable to rhinovirus, and azithromycin appears to restore them while simultaneously damping the alarmin that amplifies the inflammatory response to infection.
That dual action is a satisfying explanation, and it is worth keeping in proportion. Nothing here changes who should receive long-term azithromycin — that decision still rests on the clinical trials, on exacerbation frequency, and on the real costs of macrolide use: QT prolongation, hearing loss, and the antimicrobial resistance argument, which in Indian practice is not an abstraction given macrolide resistance rates and the parallel use of azithromycin in tuberculosis-endemic settings where atypical mycobacteria matter. The mechanism is interesting; the prescribing threshold is unchanged.
- Do not change who receives long-term azithromycin on this study; it is mechanistic, not clinical.
- The proposed mechanism is dual: restored epithelial interferon responses plus reduced interleukin-33.
- Clinical outcomes improved only numerically, in 32 analysed patients — as expected at that size.
- Continue baseline ECG and hearing enquiry before starting long-term macrolides.
- Weigh the resistance cost seriously, particularly where atypical mycobacterial disease is prevalent.
The statistics, in plain English
The key limitation is what the comparison was. The significant interferon findings are within-group changes — azithromycin patients compared with their own baseline — with the placebo group showing no such change. That is weaker than a direct between-group comparison, because it does not formally test whether the two groups differed from each other. With 16 patients per arm, a formal between-group test would be underpowered anyway. The honest reading is that this is consistent with a real biological effect and cannot establish its size. That clinical outcomes moved numerically without significance is exactly what a study of this size should be expected to show.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for pulmonology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free